Efficacy and Safety of Tenofovir Disoproxil Furmarate for Patients with Lamivudine-Resistant Hepatitis B Virus Infection

Abstract

and 89.7%, respectively. The mean change from baseline in HBV DNA was -2.05 log10IU/mL, and -2.14 log10IU/mL, respectively. Multivariate Cox regression analysis showed that baseline HBV DNA level was a significant predictive factor of virologic response at 12 months. (HR = 0.645; 95% CI 0.504-0.826; p = 0.001). Two patients (2.4%) showed HBeAg loss, and no patient lost HBsAg during the treatment period. Serious adverse events or renal impairment was not observed. CONCLUSION: TDF is safe and effective for complete viral suppression in patients with lamivudine-resistant HBV infection.